Journals / Annals of Health Sciences Research / 2020 / Cilt: 1 - Sayı: 1

Expression of COX-2, ß-catenin and p53 in Colorectal Adenomas and Adenocarcinomas

Kalın barsak adenom ve adenokarsinomlarında COX-2, ß-catenin ve p53 ekspresyonu

Pages
36–46
Publication Date
2020-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, we tought that p53 could be used bad prognostic factor for colorectal carcinomas.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Colorectal carcinoma is fourth common malignant tumor after another major causes of deaths from the malign diseases lung carcinoma, prostat carcinoma and breast carcinoma.
📊
Key Findings & Data:Colorectal carcinomas incidence rates increased with hereditary changes.
💡
Conclusion & Impact:Thus, we tought that p53 could be used bad prognostic factor for colorectal carcinomas.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kalın barsak karsinomları · adenomlar · COX-2

Abstract

Colorectal carcinoma is fourth common malignant tumor after another major causes of deaths from the malign diseases lung carcinoma, prostat carcinoma and breast carcinoma. Colorectal carcinomas incidence rates increased with hereditary changes. In this study, clinical, prognostic and histological properties of colorectal carcinomas and adenomas were investigated by using immunohistochemical markers COX-2, ßcatenin and p53. In this study, we retrespectively investigated 77 colorectal carcinomas and 42 adenomatous polyps at Department of Pathology, Düzce University Medical School. In our study 36, 25 and 16 adenocarcinomas were well, moderate and poorly differantiated, respectively. Adenomas were grouped as tubular adenoma (n=18), tubulovillous adenoma (n=15), villous adenoma (n=9). Cases were classified according to WHO. General and prognostic features of colorectal carcinomas and adenomas were investigated by applying immunoreactivities, namely COX-2, ß-catenin and p53. In our study, adenocarcinomas were expressed COX-2 more than adenomas. We found that, poorly differentiated adenocarcinomas expressed COX-2 more than well differentiated and moderately differentiated adenocarcinomas. Thus, we tought that COX-2 could be used bad prognostic factor for colorectal carcinomas. ß-catenin was similarly expressed at adenocarcinomas and adenomas. In our study, adenocarcinomas were expressed p53 more than adenomas. We found that, poorly differentiated adenocarcinomas expressed p53 more than well differentiated and moderately differantiated adenocarcinomas. Thus, we tought that p53 could be used bad prognostic factor for colorectal carcinomas.

Özet

Kalın barsak kanserleri, tüm dünyada kansere bağlı ölümlerden sorumlu akciğer, meme, prostat tümörlerinden sonra dördüncü kanser türüdür. Besin alışkanlıklarının değişmesi ile birlikte, kanser görülme sıklıkları da artmıştır. Çalışmamıza alınan kalın barsak karsinomlu ve adenoma bulunan vakaların klinik prognostik, histolojik özellikleri ve COX-2, ß-catenin ve p53 ile immünohistokimyasal olarak boyanma özellikleri araştırıldı. Düzce Üniversitesi Tıp Fakültesi Eğitim ve Araştırma Hastanesi Patoloji laboratuarında retrospektif olarak incelenen 77'si adenokarsinom, 42'si adenoma tanısı almış 119 olgu çalışma kapsamına alındı. Adenokarsinomların 36'sı iyi, 25'I orta,16'sı az diferansiye adenokarsinomdu. Adenomların ise 18'I tübülöz, 15'I tübülovillöz, 9'u ise villöz adenomdu. Vakalar WHO'nun derecelendirme ve evreleme sistemine göre sınıflandırıldı. Kalınbarsak kanser ve adenomlarının genel özellikleri, prognostic faktörleri ve COX-2, ß-catenin ve p53 immünoreaktiviteleri incelendi. COX-2 ile boyanma şiddeti ve yüzdesi değerlendirildiğinde; COX-2 ekspresyonunda adanokarsinomlarda adenomlara göre istatistiksel olarak anlamlı bir artış tespit edildi. Benzer şekilde az diferansiye karsinomlarda COX-2'nin boyanma şiddeti ve yüzdesinde istatistiksel olarak anlamlı artış izlendi. Bu nedenle COX-2'yi kötü prognozu gösteren belirteç olarak değerlendirilmiştir. ß-catenin adenokarsinom ve adenomlarda benzer immünoreaktivite gösterdi (p>0.05). Adenokarsinomlarda adenomlara göre p53 ile boyanma yüzdesi istatistiksel olarak anlamlı bir artış izlendi. Bu nedenle p53’de kötü prognozu gösteren bir belirteç olarak değerlendirilmiştir.

🔖

Cite This Article

ŞAHİN, A. F. (2020). Expression of COX-2, ß-catenin and p53 in Colorectal Adenomas and Adenocarcinomas. Annals of Health Sciences Research, Cilt: 1 - Sayı: 1, 36–46. https://ajindex.com/articles/824786

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Ferlay J. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 https://publications.iarc.fr/Databases/Iarc- Cancerbases/GLOBOCAN-2012-Estimated- Cancer-Incidence Mortality-And-Prevalence- Worldwide-In-2012-V1.0-201216.05.2019
  2. İlter H, Keskinkılıç B. 2015 yılı Türkiye Kanser İstatistikleri Halk Sağlığı Genel Müdürlüğü Kanser Savaş Daire Başkanlığı, T.C Sağlık Bakanlığı Ankara 2018
  3. Wiese FW, Thompson PA, Kadlubar FF. Carcinogen substrate specificity of human COX-1and COX-2. Carcinogenesis. 2001; 22(1): 5-10
  4. Plastaras JP, Guengerich FP, Nebert DW, MarnettLJ. Xenobiotic- metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J Biol Chem. 2000; 275(16): 11784-90
  5. Washington K, Hamilton K. Expression of beta-catenin and alfacatenin and E-cadherin inbarrett’s esophageal adenocarcinomas. Modpathol 1998; 11(9); 805-13
  6. Huiping C, Jonassan JG, et al. Alterations of Ecadherin and beta-catenin in gastic cancers. BMC Cancer 2001; 1:16-30 7. Tsuji H, Takahashi H. Nuclear localization of beta-catenin in the hair matrix cells and differantiated keratinocytes. J Dermatol Sci 2001; 27:170-7
  7. Moustafa AA, Yen L. Regulation of Ecadherin, beta-catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer 2002; 37: 49-56 9. Zhou YN, Xu CP, Han B. Expression of Ecadherin, beta-catenin in gastic carcinoma and its correlation with the clinicopathological features and patient survival. World J Gatroenterology 2002; 8(6): 987-93
  8. Aust DE, Terdiman J, et al. Altered distribution of beta catenin, and its binding proteins Ecadherinand APC, in ulserative colitis releated colorectal cancers. Modpathol. 2001; 14:29-39 11. Murata M, Iwao K, Miyoshi Y. Activation of the beta catenin gene by interstitial deletions involving exon 3 as early event in colorectal tumorigenesis. Cancer Letters 2000; 159: 73-8 12. Nilbert M, Ramberch E. beta-catenin activation through mutation is rare in rectal cancer. Cancer Genet Cytogenet 2001; 128: 43-45 13. Muro G, Munoz J, et al. Prognostic value of the expression of E-cadherin, beta-cateninin bladder cancer. Eur J Cancer 2000; 36: 357-62 14. Kumar V, Abbas AK, Fausto N. Neoplasia, chapter7, in Robbins and Cotran Pathologic Basis of Disease, 7th ed. Philadelphia: Elsevier Saunders. 2005: 269-342
  9. Seidman JD, Russel P, Kurman RJ. Surface Epithelial Tumors of the Ovary, chapter 18, Blau